Dyslipidemias – Talk Bio

Novartis Again Partners with Argo Biopharma in $5.2B+ RNAi Cardiovascular Deal

1 week ago talkbio0Tagged ANGPTL3, Biopharma, biotech collaboration, cardiovascular pipeline, Drug Development, Dyslipidemias, milestone payments, Novartis, RNA Interference, RNA, Small Interfering

Novartis; Argo Biopharma; RNA interference (RNAi); siRNA; cardiovascular pipeline; ANGPTL3; dyslipidemia; biotech collaboration; drug development; milestone payments

Solbinsiran: Eli Lilly’s Promising ANGPTL3 Inhibitor for Lipid Management

5 months ago talkbio0Tagged ANGPTL3, Dyslipidemias, Lipids, Psychological inhibition, RNA, Small Interfering, solbinsiran

ANGPTL3 inhibition, solbinsiran, dyslipidemia, lipid reduction, siRNA therapy

Rona’s Sanofi-Sourced siRNA Demonstrates Early Efficacy in Dyslipidaemia Treatment

10 months ago talkbio0Tagged development aspects, Dyslipidemias, Interferes with, Lipid Metabolism Disorders, RNA, RNA, Small Interfering, Rona, sanofi

siRNA, dyslipidaemia, Rona, Sanofi, RNA interference, lipid disorders, therapeutic development

Arrowhead’s Plozasiran Projected to Surpass $700M in Sales by 2032, Addressing Major Unmet Needs in Dyslipidemia Treatment

1 year ago talkbio0Tagged 2032, APOC3 gene, Arrowhead, cellular targeting, Dyslipidemias, Familial chylomicronemia syndrome, FCS, Fetal Bovine Serum, GlobalData, Plozasiran, Projections and Predictions, Sales - occupational activity, SHTG, Triglycerides, Unmet Needs

Arrowhead Pharmaceuticals, Plozasiran, Dyslipidemia, GlobalData, Sales Forecast, $700M, 2032, Unmet Needs, Triglyceride Reduction, APOC3 Targeting, SHTG (Severe Hypertriglyceridemia), FCS (Familial Chylomicronemia Syndrome), Mixed Dyslipidemia